Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional nimodipine for resistant cutaneous leishmaniasis
IRCT20160215026563N2Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimodipine in cutaneous leishmaniasis (CL), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Lesion size and Induration. Started Jun 2018; status: completed.
02
Drugs
nimodipine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20160215026563N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160215026563N2.